[Temporary Announcement] Global Pharmaceutical: Announcement on the Convening of the 2025 Annual Shareholders Meeting
Announcement number: 2026-011
Securities code: 835037 Securities abbreviation: Global Pharmaceuticals Sponsoring broker: Guoyuan Securities
Anhui Global Pharmaceutical Co., Ltd.
Notice and Announcement on Convening the 2025 Annual Shareholders Meeting
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.
1. Basic situation of the meeting
(1) Session of shareholders’ meeting
This meeting is the 2025 annual shareholders meeting.
(2) Convener
The convener of this shareholders' meeting is the board of directors.
(3) Explanation of legality and compliance of the meeting
The convening of this meeting complies with relevant regulations such as the Company Law and the Articles of Association.
(4) How to hold the meeting
√On-site meeting □Electronic communication meeting
Conference room on the fourth floor of the company, No. 3809, Huangshan Avenue, Bengbu City, Anhui Province.
(5) Meeting voting method
√On-site voting □Electronic communication voting
□Online voting □Other ways to vote
(6) Date and time of the meeting
- Meeting time: 14:00 on April 9, 2026.
(7) Participants
- Shareholders who hold the company’s shares on the equity registration date.
Announcement number: 2026-011
All shareholders of the company registered in CSDC at the close of the afternoon on the equity registration date (see the table below for details) have the right to attend the shareholders' meeting (investors who bought securities on the equity registration date have this right, investors who sold securities on the equity registration date do not have this right). Shareholders can entrust a proxy in writing to attend the meeting and vote. The shareholder agent does not have to be a shareholder of the company. This does not include preference shareholders or preference shareholders whose voting rights have been restored.
Class of shares Securities code Securities abbreviation Equity registration date Ordinary shares 835037 Global Pharmaceutical March 31, 2026
The company’s directors, supervisors, senior managers and persons in charge of information disclosure affairs.
Arrangements for lawyer witnessing.
Lawyer at Shanghai Tianyanhe Law Firm.
2. Matters to be considered at the meeting
Proposal Voting shareholder type
Motion name
No. Non-Cumulative Voting Proposal of Ordinary Shareholders
1 "2025 Annual Report and Summary" √
2 "2025 Board of Directors Work Report" √
3 "2025 Work Report of the Board of Supervisors" √
4 "2025 Financial Final Accounts Report" √
5 "2026 Financial Budget Report" √
6 "2025 Equity Distribution Plan" √
7 "Proposal on using own idle funds to purchase bank financial products" √
8 "Proposal to Re-appoint the Company's Financial Audit Agency for 2026" √
For details, please refer to the company’s announcement on the designated information disclosure platform of the National Equities Exchange and Quotations.
Announcement number: 2026-011
"Announcement on Resolutions of the Sixth Meeting of the Ninth Board of Directors" (Announcement No.: 2026-002), "Announcement on Resolutions of the Sixth Meeting of the Ninth Board of Supervisors" (2026-003), "2025 Annual Report and Summary" (2026-005), "2025 "Annual Equity Distribution Plan" (2026-006), "About using its own idle funds to purchase bank financial products" (2026-007), "Re-appointment of the company's financial audit agency for 2026" (2026-008).
There is no special resolution motion for the above motion;
There is no separate counting of votes for small and medium investors in the above proposals;
There is no resolution for related shareholders to avoid voting on the above proposals;
The above-mentioned proposal does not involve the public issuance of shares and listing on the Beijing Stock Exchange.
3. Meeting registration method
(1) Registration method
The representative of a legal person shareholder shall register with the legal person's shareholding certificate, securities account card, legal representative certificate or legal person's power of attorney, a copy of the business license and the ID card of the attendee.
Natural person shareholders shall register with their ID cards, securities account cards, and shareholding certificates. The agent shall register with his/her identity card, power of attorney, client's securities account card, and shareholding certificate.
Registration procedures can be done by letter or fax, but telephone registration is not accepted.
(2) Registration time: April 9, 2026 8:30-12:00
(3) Registration location: Office of the Company’s Board of Directors, No. 3809, Huangshan Avenue, Bengbu City, Anhui Province.
4. Others
(1) Meeting contact information: Contact person: Li Chao Tel: 0552-4098308 Email: [email protected] Address: Office of the Company’s Board of Directors, No. 3809 Huangshan Avenue, Bengbu City, Anhui Province
room
(2) Meeting expenses: This meeting is expected to last half a day, and shareholders participating in the meeting will bear their own expenses such as transportation, food and accommodation.
5. Documents for reference
"Resolution of the Sixth Meeting of the Ninth Board of Directors";
"Resolution of the Sixth Meeting of the Ninth Supervisory Board".
Announcement number: 2026-011
Anhui Global Pharmaceutical Co., Ltd. Board of Directors
March 20, 2026
Attachments:
Power of attorney
The power of attorney shall include the principal's basic information, including but not limited to the principal's name (or name of the legal person shareholder's unit), ID number (or legal person shareholder's business license number), legal representative of the legal person shareholder, shareholder account, and number of shares held; basic information about the agent, including but not limited to the agent's name, ID number; agency matters, authority, and term. The power of attorney must be signed by the principal (with the official seal of the legal person shareholder and the signature of the legal representative).